Business context and reporting period
The filing is Zafgen, Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2019. The supplied metadata names Larimar Therapeutics, Inc., but the filing text identifies the registrant as Zafgen, Inc. (ticker ZFGN).
Zafgen was a clinical-stage biopharmaceutical company with no product revenue. After preliminary animal-study results suggested a low near-term probability of resolving the FDA’s full clinical hold on lead candidate ZGN-1061, the company withdrew its IND and halted further development of MetAP2 inhibitors in September 2019. It began evaluating strategic alternatives, including a possible acquisition, merger, business combination, or other transaction.
Financial results and liquidity
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $5.3 million | $11.8 million | $23.5 million | $36.5 million |
| General and administrative expense | $3.6 million | $3.3 million | $10.9 million | $10.0 million |
| Restructuring charges | $4.0 million | — | $4.0 million | — |
| Net loss | $12.9 million | $15.1 million | $38.2 million | $46.8 million |
| Net loss per share | $0.35 | $0.41 | $1.02 | $1.53 |
- At September 30, 2019, cash and cash equivalents were $43.3 million, marketable securities were $38.7 million, and restricted cash was $1.3 million. Cash, cash equivalents and marketable securities totaled approximately $82.0 million.
- Operating cash use for the first nine months was $31.0 million, compared with $39.7 million in 2018. Cash, cash equivalents and restricted cash decreased by $4.7 million during the period.
- Term-loan principal outstanding was $16.4 million: $7.3 million current and $9.1 million long-term principal, with an additional $1.1 million of long-term accretion related to the final payment. The loan bears variable interest; its effective annual rate was approximately 9.4% at quarter-end. Principal is scheduled through December 2021.
- Total current assets were $83.4 million and current liabilities were $16.3 million. Total liabilities were $33.0 million; stockholders’ equity was $59.9 million.
- No operating margin or profitability measure is meaningful because the company had no revenue and reported operating losses. Accumulated deficit was $389.1 million.
Material changes versus the prior comparable period
- Q3 net loss narrowed by $2.2 million year over year; nine-month net loss narrowed by $8.6 million. Lower R&D spending, including no clinical trials in 2019 versus a Phase 2 ZGN-1061 trial in Australia and New Zealand in 2018, was the main driver.
- Q3 R&D expense fell $6.6 million year over year and nine-month R&D fell $13.0 million. Lower MetAP2 program costs and reduced personnel and stock-based compensation contributed.
- G&A expense increased $0.3 million in Q3 and $0.9 million for the nine-month period, with strategic-alternatives and legal fees among the stated factors.
- The company recorded $4.0 million of Q3 restructuring charges, including severance, contract termination, and facility-closure costs. It reported a 70% total workforce reduction from 2019 actions and attrition, and expected approximately $5.6 million in annual personnel cost savings.
- Marketable securities declined to $38.7 million from $68.7 million at year-end 2018; cash and cash equivalents declined to $43.3 million from $49.3 million. The 2018 comparison included $64.6 million in net proceeds from a public offering; there was no comparable offering in 2019.
Outlook, risks, contingencies and unusual items
- Management stated that available cash, cash equivalents and marketable securities were expected to fund anticipated operations, capital expenditures, and debt repayments for at least 12 months from the filing’s issuance date. The company expected continued operating losses and said its estimates could prove inaccurate.
- Strategic-alternative discussions were ongoing, with no assurance of a transaction, its timing, or value to shareholders. The company had engaged an investment bank to review alternatives.
- The term loan includes minimum-liquidity requirements, restrictive covenants, and a material-adverse-event default provision. Management assessed subjective acceleration as reasonably possible but not probable; lender action or the company’s assessment could change. Failure to satisfy certain liquidity requirements could require restricted cash or expose the company to loan remedies.
- Nasdaq notified the company that its share price had fallen below the $1.00 minimum bid requirement. It had until March 16, 2020 to regain compliance, with possible delisting and reduced trading liquidity if it failed.
- The September restructuring left $3.6 million of accrued costs, expected to be paid within 12 months; management did not expect significant additional restructuring costs. In October 2019, after quarter-end, the company transferred sponsorship and data rights for its Prader-Willi natural-history study to the Foundation for Prader-Willi Research.
- The company disclosed no material legal proceedings. It also reported no off-balance-sheet arrangements and stated that disclosure controls were effective as of September 30, 2019.
Most important facts for investors to verify
- Confirm the issuer identity: this filing is for Zafgen, Inc., despite the Larimar Therapeutics metadata.
- Check the status and outcome of the strategic-alternatives process, including whether any transaction was completed and on what terms.
- Verify subsequent cash burn, available liquidity, and compliance with the term-loan covenants and repayment schedule.
- Confirm whether the company regained Nasdaq minimum-bid compliance or faced delisting, and whether its capital structure or share count changed.
- Review subsequent disclosures on the discontinued MetAP2 programs, restructuring payments, and any liabilities or obligations tied to licenses and leases.